SL Science Holding Ltd
SL Science Holding Limited (SLBT) reported a 23% revenue increase to $1.39M for H1 2026, with gross margin expanding to 40.2%. Costs rose, leading to a wider net loss of $2.16M. The company completed its Nasdaq listing and advanced its cell therapy programs, including FDA filings and a PIPE financing of $7.8M. SLBT closed at $1.23, up 6.96%.
SL Science Holding Limited reported 1H Non-GAAP EPS of $0.00 and revenue of $1.38B, according to the company. The firm has a valuation of $1.15B based on preclinical promises.
SL Science Holding Ltd (SLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SL Science Holding Limited Reports First Half 2026 Financial Results Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs compared with last period due to establishment of stable
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning SLBT (SL Science Holding Ltd). Coverage has skewed bearish: 0 bullish, 2 neutral, and 2 bearish.
Recent SLBT coverage spans earnings, regulation and market movers.
In the last 30 days, SLBT insiders filed 1 SEC Form 4 transaction — 1 purchase ($2.3M) and no sales. The most active reporter was Wang Ching-Dong, Chief Executive Officer, with 1 filing.
Earnings beat on revenue and margin may support short-term upside despite higher loss.
Earnings miss on profit metric likely triggers sell pressure.
The earnings beat on revenue growth and cash infusion may attract short‑term buying, but rising losses and higher operating expenses temper upside.
Insider purchase signals confidence and may support short-term price upside.
Recent volatility persists.
AlphAI scores every news story that mentions SLBT with an AI model for sentiment and relevance, and aggregates insider trades from SL Science Holding Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
SL Science Holding Limited (SLBT) reported a 23% revenue increase to $1.39M for H1 2026, with gross margin expanding to 40.2%. Costs rose, leading to a wider net loss of $2.16M. The company completed its Nasdaq listing and advanced its cell therapy programs, including FDA filings and a PIPE financing of $7.8M. SLBT closed at $1.23, up 6.96%.
1 min readSL Science Holding Limited reported 1H Non-GAAP EPS of $0.00 and revenue of $1.38B, according to the company. The firm has a valuation of $1.15B based on preclinical promises.
1 min readSL Science Holding Ltd (SLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SL Science Holding Limited Reports First Half 2026 Financial Results Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs compared with last period due to establishment of stable
2 min readWang Ching-Dong (Chief Executive Officer) purchased 4,545,306 indirectly-held shares of SL Science Holding Ltd (SLBT) at $0.50 ($2.27M total) on 2026-09-29.
1 min readNetApp (NTAP) shares dropped 8.2% in pre-market trading despite beating Q1 earnings and revenue estimates. Other stocks moving lower include Ultragenyx (RARE), Methode Electronics (MEI), and Hewlett Packard Enterprise (HPE).
3 min readSL Science Holding Limited (SLBT) filed a Master Drug File (MDF) with the FDA for exosomes derived from Gamma Delta T (GDT) cells, which are being developed to treat brain and pancreatic cancers. The filing was made by JY BioMed Co Ltd, an investor and IP rights holder. SLBT's stock closed at $2.64 on Thursday, down to $2.58 in afterhours trading.
1 min readSL Science (NASDAQ: SLBT) announced that JY BioMed filed a new FDA Drug Master File (DMF) for GDT cell-derived exosomes, expanding regulatory documentation. This milestone covers exosomes and GDT cells, potentially streamlining future regulatory processes. The exosomes may address delivery challenges in oncology, including crossing the blood-brain barrier for brain cancer treatment.
2 min readBiotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI
3 min readSL Science Holding Limited (Nasdaq: SLBT) said it submitted an FDA Orphan Drug Designation request for its Vdelta2+ Gamma Delta T cell therapy to treat glioblastoma multiforme (GBM). The FDA’s OOPD acknowledged receipt and is reviewing additional files. The company’s licensor JY BioMed will present related preclinical data at WCP 2026.
4 min readSL Science Holding Limited (formerly SL BIO Ltd.) began trading on Nasdaq as SLBT in mid-June 2026 after a SPAC merger with Horizon Space Acquisition II Corp. The company develops gamma delta T cell and gene therapies for solid tumors. Shares have swung roughly $3.00–$14.50 (52-week range) with >30% intraday moves; the deal valued equity at ~$5.568B and included a $7.8M PIPE.
7 min read
